Jeff Aronin recalls a life-changing meeting he had with a physician. The physician told Aronin that he had a problem. He had a patient who was a child suffering from seizures. He had two choices of treatment: A complex surgery or a medication that was probably less effective. He said he had decided to go with the medicine since doing so would save the child the complexities and hardship of a long, arduous surgery. It was this conversation that helped Aronin decide to spend the rest of his life in medical research to making medicine much more effective.
He had a particularly strong desire to create new medicines for rare diseases that did not yet have a medical treatment. Drugs for such diseases were very mostly non-existent because up to that time most pharmaceutical companies only concentrated on common afflictions. Aronin entered adult life by attending and graduating with a B.A. and then an M.B.A. from DePaul University. After graduation, he immediately entered the healthcare industry. After a few years, he founded and became CEO of Ovation Pharmaceuticals LLC in 2000.
In 2009 sold the company to the Danish healthcare company, Lundbeck, for $900 million. After the sale, Aronin continued to lead it to continued growth as both its CEO and president. He is today one of the world’s top biotech and healthcare professionals. He has been instrumental in helping develop over a dozen new medicines and technologies. He is also the current chairman and CEO of Paragon Biosciences. He has filled this particular leadership role for ten years. He also has leadership roles with Castle Creek Pharmaceuticals and Harmony Biosciences.
Aronin is also committed to teaching and mentoring the next generation of healthcare workers. To this end, he has started Matter which is working to develop over 200 medical startup companies for future medical workers.